

MENVEO™

non-live (conjugate) meningococcal
groups A, C, W-135, Y vaccine

Men-C-ACYW-CRM

≥ 2 months[‡] to 55 years

DIN 02417030



SUPPLIED:

single-dose vial lyophilized component, vial liquid component; needle/syringe not supplied



PREPARATION:

RECONSTITUTE
prior to
administration



ADMINISTRATION:

IM
injection



**APPROPRIATE
USE:**

- May be publicly funded in SK
- See QR code for recommendations for use.



CIG



**BEYOND-USE
EXPIRY
DATE/TIME:**

- Check date on carton (expiry date). The lyophilized vial and liquid vial may have different expiry dates.
- **Not reconstituted:** 2°C to 8°C: use vaccine until expiry date.
- **Reconstituted:** at or below 25°C; use vaccine within 8 hours.



HANDLING:

- Shake vial vigorously when reconstituting.



APPEARANCE:

- Reconstituted vaccine is a clear, colourless solution.
- NO foreign particulate matter/discolouration



DOSE:

- 0.5 mL



SERIES/SCHEDULE:

PRIMARY SERIES:

≥ 2 years[‡]: | 1-dose[^]

[^] Individuals at high risk due to underlying medical conditions require 2 doses given at least 8 weeks apart. See QR code for details.

BOOSTER: May be required in some situations. See QR code for details.

[‡] Pharmacists can immunize those 5 years and older.

^{*} as per the CIG

REFERENCES:

- [MENVEO™ product monograph](#)
- [Saskatchewan Immunization Manual Chapter 10](#)
- [Canadian Immunization Guide: Meningococcal vaccines](#)
- [CATMAT Statement on Meningococcal Disease and the International Traveller](#)

Financial contribution:



Public Health
Agency of Canada

Agence de la santé
publique du Canada

25 MAR 2024

©2024 medSask // Townes & Park Designs